|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DDO |
Gene summary for DDO |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DDO | Gene ID | 8528 |
| Gene name | D-aspartate oxidase | |
| Gene Alias | DASOX | |
| Cytomap | 6q21 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q99489 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8528 | DDO | P2T-E | Human | Esophagus | ESCC | 4.75e-03 | 5.82e-02 | 0.1177 |
| 8528 | DDO | P10T-E | Human | Esophagus | ESCC | 9.63e-120 | 2.16e+00 | 0.116 |
| 8528 | DDO | P28T-E | Human | Esophagus | ESCC | 2.01e-75 | 1.43e+00 | 0.1149 |
| 8528 | DDO | P39T-E | Human | Esophagus | ESCC | 4.47e-51 | 9.96e-01 | 0.0894 |
| 8528 | DDO | P49T-E | Human | Esophagus | ESCC | 5.06e-29 | 2.55e+00 | 0.1768 |
| 8528 | DDO | P56T-E | Human | Esophagus | ESCC | 1.26e-29 | 3.27e+00 | 0.1613 |
| 8528 | DDO | P62T-E | Human | Esophagus | ESCC | 1.18e-02 | 9.19e-02 | 0.1302 |
| 8528 | DDO | P74T-E | Human | Esophagus | ESCC | 1.47e-89 | 2.42e+00 | 0.1479 |
| 8528 | DDO | P80T-E | Human | Esophagus | ESCC | 1.48e-03 | 1.49e-01 | 0.155 |
| 8528 | DDO | P89T-E | Human | Esophagus | ESCC | 7.68e-36 | 2.50e+00 | 0.1752 |
| 8528 | DDO | P104T-E | Human | Esophagus | ESCC | 2.51e-15 | 1.64e+00 | 0.0931 |
| 8528 | DDO | P128T-E | Human | Esophagus | ESCC | 6.19e-78 | 2.53e+00 | 0.1241 |
| 8528 | DDO | P130T-E | Human | Esophagus | ESCC | 1.22e-131 | 3.24e+00 | 0.1676 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
| GO:003164710 | Cervix | CC | regulation of protein stability | 63/2311 | 298/18723 | 1.14e-05 | 2.45e-04 | 63 |
| GO:004211013 | Cervix | HSIL_HPV | T cell activation | 48/737 | 487/18723 | 5.12e-09 | 7.61e-07 | 48 |
| GO:003164715 | Cervix | HSIL_HPV | regulation of protein stability | 31/737 | 298/18723 | 8.69e-07 | 4.19e-05 | 31 |
| GO:004211022 | Cervix | N_HPV | T cell activation | 39/534 | 487/18723 | 7.04e-09 | 1.58e-06 | 39 |
| GO:003164725 | Cervix | N_HPV | regulation of protein stability | 17/534 | 298/18723 | 5.47e-03 | 3.90e-02 | 17 |
| GO:0031647 | Colorectum | AD | regulation of protein stability | 108/3918 | 298/18723 | 6.33e-10 | 5.08e-08 | 108 |
| GO:0018279 | Colorectum | AD | protein N-linked glycosylation via asparagine | 15/3918 | 23/18723 | 5.47e-06 | 1.40e-04 | 15 |
| GO:0018196 | Colorectum | AD | peptidyl-asparagine modification | 15/3918 | 24/18723 | 1.18e-05 | 2.62e-04 | 15 |
| GO:0006487 | Colorectum | AD | protein N-linked glycosylation | 25/3918 | 65/18723 | 9.12e-04 | 8.71e-03 | 25 |
| GO:0006486 | Colorectum | AD | protein glycosylation | 64/3918 | 226/18723 | 4.86e-03 | 3.27e-02 | 64 |
| GO:0043413 | Colorectum | AD | macromolecule glycosylation | 64/3918 | 226/18723 | 4.86e-03 | 3.27e-02 | 64 |
| GO:0070085 | Colorectum | AD | glycosylation | 67/3918 | 240/18723 | 5.78e-03 | 3.67e-02 | 67 |
| GO:00316471 | Colorectum | SER | regulation of protein stability | 86/2897 | 298/18723 | 2.56e-09 | 2.42e-07 | 86 |
| GO:00182791 | Colorectum | SER | protein N-linked glycosylation via asparagine | 9/2897 | 23/18723 | 5.20e-03 | 3.95e-02 | 9 |
| GO:00181961 | Colorectum | SER | peptidyl-asparagine modification | 9/2897 | 24/18723 | 7.19e-03 | 4.99e-02 | 9 |
| GO:00316472 | Colorectum | MSS | regulation of protein stability | 103/3467 | 298/18723 | 2.52e-11 | 3.49e-09 | 103 |
| GO:00182792 | Colorectum | MSS | protein N-linked glycosylation via asparagine | 13/3467 | 23/18723 | 5.21e-05 | 9.31e-04 | 13 |
| GO:00181962 | Colorectum | MSS | peptidyl-asparagine modification | 13/3467 | 24/18723 | 9.44e-05 | 1.49e-03 | 13 |
| GO:00064871 | Colorectum | MSS | protein N-linked glycosylation | 23/3467 | 65/18723 | 9.47e-04 | 9.54e-03 | 23 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041467 | Esophagus | ESCC | Peroxisome | 55/4205 | 82/8465 | 1.04e-03 | 3.27e-03 | 1.68e-03 | 55 |
| hsa0414612 | Esophagus | ESCC | Peroxisome | 55/4205 | 82/8465 | 1.04e-03 | 3.27e-03 | 1.68e-03 | 55 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DDO | SNV | Missense_Mutation | novel | c.346G>A | p.Gly116Ser | p.G116S | Q99489 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-A7-A4SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| DDO | SNV | Missense_Mutation | c.914N>G | p.Leu305Trp | p.L305W | Q99489 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| DDO | insertion | Frame_Shift_Ins | novel | c.574_575insTGGAGCCCTCCCTCCACGGAGCCTGCAACATCAGGGAGAAGGTG | p.Arg192LeufsTer18 | p.R192Lfs*18 | Q99489 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| DDO | insertion | Frame_Shift_Ins | novel | c.633_634insCAGGCCAGGCGTGCGACTGCAGACAGAGCTCCTTGCGCGAGATGGAC | p.Gly212GlnfsTer32 | p.G212Qfs*32 | Q99489 | protein_coding | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| DDO | SNV | Missense_Mutation | c.803N>T | p.Gly268Val | p.G268V | Q99489 | protein_coding | deleterious(0) | possibly_damaging(0.732) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DDO | SNV | Missense_Mutation | c.814N>A | p.Leu272Met | p.L272M | Q99489 | protein_coding | tolerated(0.06) | possibly_damaging(0.625) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| DDO | SNV | Missense_Mutation | rs755822127 | c.854G>A | p.Arg285Gln | p.R285Q | Q99489 | protein_coding | tolerated(0.24) | probably_damaging(0.999) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| DDO | SNV | Missense_Mutation | c.669N>T | p.Lys223Asn | p.K223N | Q99489 | protein_coding | tolerated(0.21) | benign(0.001) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD | |
| DDO | SNV | Missense_Mutation | rs770028862 | c.686G>A | p.Gly229Asp | p.G229D | Q99489 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| DDO | SNV | Missense_Mutation | novel | c.1000N>A | p.His334Asn | p.H334N | Q99489 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8528 | DDO | DRUGGABLE GENOME | topotecan | TOPOTECAN | 24444404 | |
| 8528 | DDO | DRUGGABLE GENOME | MALONIC ACID | MALONIC ACID | 26322531 | |
| 8528 | DDO | DRUGGABLE GENOME | 5-AMINONICOTINIC ACID | CHEMBL1491941 | 26322531 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |